Gilead Sciences (NASDAQ:GILD) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Gilead Sciences (NASDAQ:GILD) issued its earnings results on Tuesday. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23, Zacks reports. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences updated its FY 2025 guidance to 7.700-8.100 EPS.

Gilead Sciences Stock Performance

GILD traded up $0.66 during trading hours on Tuesday, hitting $96.14. The company’s stock had a trading volume of 6,050,620 shares, compared to its average volume of 6,925,933. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $119.82 billion, a PE ratio of 1,068.22, a PEG ratio of 1.25 and a beta of 0.18. The company has a 50-day simple moving average of $93.07 and a 200 day simple moving average of $86.99.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Oppenheimer upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Piper Sandler increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 in the last three months. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.